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ABSTRACT  
Objective: Side effects and development of tolerance to antiepileptic drugs necessitate identifying alterative and improved approaches to treat 
epilepsy. Bacopa monniera (BM), is a natural product which is used to treat epilepsy. We evaluated effect of co-administration of BM with 
phenobarbitone (PHB) to prevent development of tolerance to PHB.  
Methods: Male Swiss albino mice (25-30 gm-) were divided into six groups. Group 1 and 2 served as controls, which received vehicle and PHB (25 
mg/kg, i. p.) respectively. In Group 3 maximal electric shock (MES) was induced two hs following administration of PHB (25 mg/kg, i. p.) at alternate day 
for 18 d. Hind limb tonic extension (HLTE) occurrence on two consecutive days was set as end point. In Group 4, 5 and 6 MES was induced 2 h following 
co-administration of PHB (25 mg/kg, i. p.) and BM (250, 500 or 750 mg/kg p. o. respectively). Mice behavior tests were performed at the end of 
the18thday, following which mice were sacrificed and brain was isolated for estimation of malonoldehyde (MDA) and reduced glutathione (GSH) levels.  
Results: 82.5% of mice from group 3 developed tolerance to antiepileptic effects of PHB. Co-administration of BM (250, 500 and 750 mg/kg) lead to 
development of PHB tolerance in 82.5%, 25% and 20% respectively. This beneficial effect of BM was associated with reduced MDA levels and 
increased GSH levels in brain, suggesting a role of antioxidant pathways in preventing development of tolerance to antiepileptic effects of PHB.  
Conclusion: Co-administration of BM prevented the development of tolerance to antiepileptic effects of PHB. 
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INTRODUCTION 
Epilepsy is a common neurological disorder affecting over 50 million 
patients globally [1] with an incidence rate of 2–10 per 1000 
populations in the South Asia region [2]. Despite the availability of 
several antiepileptic drugs (AED), epilepsy can only be controlled and 
not cured, with surgery as an option in some difficult cases. Of concern 
are up to 30% of epileptic patients (medically intractable epilepsy or 
pharmaco-resistant seizures) in whom the seizures cannot be 
controlled even with the best available medications[3]Phenobarbitone 
(PHB) is one of the most commonly prescribed AED in developing 
countries due to its efficacy and cost effectiveness. However, 
development of tolerance to antiepileptic effect of PHD is of clinical 
concern [4]. Resistance to antiepileptic drugs can be either primary or 
acquired. In primary resistance, the patient doesn’t respond to the 
AED from the beginning of treatment and the disease persists in spite 
of regular drug therapy. While in acquired resistance, patients achieve 
initial positive therapeutic response but show recurrence of disease 
despite continuation of treatment.  
Alternative medicine practice such as use of natural products 
constitutes a sizable part of global health care system. Many plant-
based products are used in the management of epileptic seizures 
due to their cost effectiveness and relatively minimal side effects. 
Bacopa monniera (BM) (Family: Scrophulariaceae) commonly 
known as bramhi, found in India and Nepal is commonly used to 
treat CNS disorders. Bacosides A and B (a mixture of 2 saponins in 
BM), are reported to improve learning and memory and attenuate 
the retrograde amnesia produced by immobilization induced stress, 
electroconvulsive shock and scopolamine. Bacosides besides their 
antioxidant effects [5], enhance protein kinase activity and increase 
protein content in the hippocampus, which may lead to its memory 
enhancing effect [6]. High (close to 50% of LD50) but not low 
(approaching 25% of LD50) doses of BM extract given for 15 d 
demonstrated anticonvulsant activity [7]. Backsides are reported to 
potentiate the therapeutic antiepileptic effect by reversing the 
alteration in glutamate receptor binding and NMDA R1 gene 
expression in the hippocampus of the temporal lobe of epileptic rats 
[8]. Hence in the present study we evaluated the effects of co-
administration of BM extracts on the development of tolerance to 
antiepileptic effects of phenobarbitone (PHB). 
MATERIALS AND METHODS 
Chemical 
Bacopa monnieri (whole plant) plant extract was obtained from 
Natural Remedies Pvt Ltd, Bangalore, Karnataka, India. Methanolic 
extracts of Bacopa monnieri were prepared, concentrated using rotary 
evaporation and freeze dried until use. The profiling of plant extracts 
and a certificate of analysis was provided by Natural Remedies Pvt Ltd. 
The BM plant extracts had bacosides content of>40%. DMSO 
(Dimethyl sulfoxide) used as diluents. Phenobarbitone was obtained 
from Nichlos Piramal pvt Ltd Mumbai, India.  
Experimental animals-Adult male Swiss Albino mice weighing 25-30 g 
were used in our study and kept in the animal house of AIIMS, 
Department of Pharmacology, Ansari Nagar, New Delhi, India. The 
animals were acclimatized for one week, prior to the experiments. 
All the experimental procedures were approved by the standing 
Institutional Animal Ethics Committee (IAEC) of AIIMS, New Delhi, 
India (AIIMS IAEC, No. 574/2010). 
Experimental protocol  
Albino mice were divided into six groups of six mice each. Group 1 
served as vehicle control, group 2 received PHB (25 mg/kg, i. p.) for 
18 d, group 3 received PHB (25 mg/kg, i. p.) with MES (50 mA, 299 
pulse/s, 0.2 s) alternate day; Group 4, 5 and 6 received Bacopa 
monniera (250, 500 and 750 mg/kg, p. o) respectively for 18 d along 
with PHB and MES treatment. Bacopa monniera dose selection was 
based on the previous study [7]. 
Maximal electroshock seizures (MES) 
The MES model as described by Goodman & colleagues was used [9] 
Briefly, before applying the Ear clip electrodes, the ears of the mouse 
were wiped with cotton soaked in normal saline. The shock was 
delivered using ECT unit (57800-001, UGO Basile, Italy). The 
frequency (299 p/s), current duration (0.2s) and pulse width 
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(0.9ms) were kept constant while the current intensity varied. The 
mice were observed for incidence latency and duration of hind limb 
tonic extension (HLTE). The mice were screened for presence of 
hind limb tonic extension (HLTE) in response to standard maximal 
electroshock (MES) challenge. Those mice responding with HLTE 
were used for further experimentation.  
Phenobarbitone induced tolerance for MES mice model 
Animals were treated with 100% protective anticonvulsant dose of 
phenobarbitone (PHB) i.e., 25 mg/kg/day i. p., 2 h prior to maximal 
electroshock [10]. Electroshock was repeated every alternate day 
while phenobarbitone was administrated daily until the mice 
developed tolerance to PHB (evident from HLTE on two consecutive 
tests or 18 d whichever are earlier). 
Effect of Bacopa monniera on tolerance 
The mice were screened prior to the experiment and only those mice 
showing HLTE in response to convulsive stimuli were used for the 
study. Mice were co-administered PHB (25 mg/kg/day i. p.) and 
Bacopa monniera (250, 500 or 750 mg/kg/day, p. o) and 120 min 
later electroshock was administered and tested for development of 
tolerance to PHD as described above. 
Parameters studied 
Behavioral studies 
In order to assess the effect of different treatment protocols on 
cognition in mice, thee different tests were performed i.e., Closed 
field activity was using actophotometer, Grip strength scores and 
Elevated plus maze [11].  
These tests were assessed on initiation of protocol and at the end of 
protocol i.e. day 19. 
Closed field activity test 
Each mouse was observed for a period of 10 min in square closed 
arena equipped with infrared light sensitive photocells using a 
digital photo actometer (Techno, India Ltd.). 
Grip test  
The apparatus has a string of 50 cm lengths, pulled taut between two 
vertical supports and elevated to 40 cm from a flat surface. The mouse is 
placed on the string at a point midway between supports and evaluated 
according to the following scale: 0–fall off, 1-hangs onto string by two 
forepaws, 2-as for 1 but attempts to climb on string, 3-hangs onto string 
by two forepaws plus one or both hind paws, 4-hangs onto string by all 
fore paws plus tail wrapped around string, 5-escape. 
Elevated plus maze 
The apparatus consists of two open arms and two enclosed arms 
perpendicular to each other and is elevated from the ground. The 
mouse is placed on the open arm facing outwards and the transfer 
latency (TL) (the time in which the mice moves from the open arm to 
the closed arms) was recorded. On the next day, the mouse is placed 
similarly on the open arm and the TL is recorded. 
Biochemical parameters 
Oxidative stress 
The oxidative stress markers, malondialdehyde (MDA) and reduced 
glutathione levels (GSH) were estimated in mouse whole brain tissue 
homogenate after 18 d in all 6 groups. The mice were decapitated 
under ether anesthesia and the brain was quickly removed, cleaned 
by rinsing with chilled normal saline and stored at -20 °C until 
analysis. The biochemical analysis was performed within 1 w. 
Malondialdehyde (an indicator of lipid peroxidation) and reduced 
glutathione were estimated as described by Ohkawa et al., (1979) 
[12] and Ellman et al., (1959) [13] respectively. 
Statistical analysis 
The data are expressed as mean±SEM. Results were analyzed using 
one-way ANOVA followed by Dunnett’s t-test. p<0.05 is considered 
to be statistically significant. 
 
Fig. 1: Effect of Bacopa monniera on development of tolerance to 
phenobarbitone in mice 
 
 
Fig. 2: Effect of Bacopa monniera on spontaneous locomotor 
activity using actophotometer in mice (10 min) 
Each value represents mean±SEM for 6 mice 
@ p value for comparison with normal control group 
# p value for comparison with PHB+MES group 
* p<0.05; $ p>0.05 
 
 
Fig. 3: Effect of Bacopa monniera on elevated plus maze in mice 
Each value represents mean±SEM for 6 mice 
@ p value for comparison with normal control group 
# p value for comparison with PHB+MES group 
* p<0.05; $ p>0.05 
 
 
Fig. 4: Effect of different doses of Bacopa monniera on grip 
strength in mice 
Each value represents mean±SEM for 6 mice 
@ p value for comparison with normal control group 
# p value for comparison with PHB+MES group * p<0.05; $ p>0.05 
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Effect of BM on development of tolerance 
At the end of the 18 d, 82.5% of mice from group 3 (PHB+MES) and 
62.5% of the mice from group 4 (BM 250 mg/kg group) developed 
tolerance to PHB. However, in BM 500 mg/kg and 750 mg/kg, only 
25% and 20% mice developed tolerance to PHB respectively (fig. 1). 
Effect on behavioral studies 
Effect on closed field activity 
A decline in activity counts was associated with development of 
tolerance to PHB. This was evident in groups 3 and 4. Higher doses 
of BM 500 and 750 mg/kg, not only prevented the development of 
tolerance but also prevented decline in activity counts (fig. 2). 
Effect on elevated plus maze 
A significant increase in latency time was observed in tolerant mice 
and BM 250 groups in comparison to normal control suggesting 
impairment of memory. While in BM 500 and 750 mg/kg groups 
significant reduction in latency time was observed as compared to 
tolerant mice suggesting that BM 500 and 750 mg/kg prevented the 
development of tolerance and collaterally improved cognitive 
function (fig. 3). 
Effect on grip test scores  
Statistically significant decline in grip test score was observed in 
tolerant mice however all BM administered groups had no effect on 
grip scores when compared to tolerant mice (fig. 4). 
Biochemical estimations 
Level of reduced GSH in resistant mice brain  
A significant change was observed in the reduced GSH level between 
normal, control and tolerant group. BM at doses 250 and 500 mg/kg 
did not significantly alter the brain reduced GSH level in comparison 
to normal control and tolerant mice. At the dose of 750 mg/kg 
significant increases in brain reduced GSH levels were observed 
compared to tolerant mice (table 1). 
 
Table 1: Effect of Bacopa monniera administered during development of tolerance to phenobarbitone on GSH&MDA levels in mice brain 
Groups GSH (nmol/g wet tissue) MDA (µg/g wet tissue) 
Normal control 109.2±21.01 43.9±4.84 
MES control 91.6±4.24 158.13±12.22 
PHB+MES 68.5±9.58@*** 222.5±16.01@*** 
PHB+MES+Bacopa moniera 250 mg/kg 74.6±12.62#$ 163.7±17.0#* 
PHB+MES+Bacopa moniera 500 mg/kg 80.3±19.27#$ 151.3±23.28#* 
PHB+MES+Bacopa moniera 750 mg/kg 92.5±20.41#* 149.8±22.48#* 
Each value represents mean±SEM for 6 mice 
@ p value for comparison with the normal control group, # p value for comparison with PHB+MES group, * p<0.05, *** p<0.001, $ p>0.05 
 
Effect of drug resistance on level of MDA in mice brain 
The level of MDA was significantly increased in mice developing 
tolerance to PHB as compared to a normal control group. Treatment 
with BM at all dose levels significantly decreased the brain MDA 
levels as compared to tolerant mice (table 1). 
DISCUSSION 
Pharmacoresistance is encountered in nearly one third of epileptic 
patient leading to consequences such as shortened life spans (higher 
incidence of sudden deaths), social disability owing to psychiatric issues 
and other AED related toxicities [14]. The Phenomenology of pharmaco 
resistance is complex with even controlled patients relapsing and 
eventually developing resistant epilepsy. While previously resistant 
patients would experience remission (about 4% of adult epileptic 
patients per year), of which a sizable proportion eventually relapse [15]. 
However, a subgroup of patients may have constitutional or inherent 
resistance. Although the treatment strategies for resistant patients may 
vary from curative or palliative surgery, procedures such as vagal nerve 
stimulation, ketogenic diet, these have limited utility and hence search is 
on for newer more effective AED [16, 17]. 
Many drug related factors have also been implicated in the 
development of pharmacoresistance. Of these, `tolerance' is an 
important drug related factor [18]. Tolerance is reported to all AED 
[19] eventually leading to drug resistance. Hence strategies 
ameliorating tolerance development would prevent development of 
drug resistance at least in some patients. We tested once such 
approach in our study. The effect of extracts of Bacopa monnieri 
(BM) on the development of tolerance to antiepileptic effects of PHB 
was evaluated. Several studies have reported the anticonvulsant 
action [7] and learning and memory enhancement [20] effects of BM. 
Here it is also worthwhile to mention that BM has been used to treat 
various CNS disorders for a long period and is shown to be safe with 
very potent antioxidant activity. 
Alteration in oxidative stress leading to pharmacoresistance is well 
reported, for instance increased production of ROS may modify ion 
channel properties and lead to pharmacoresistance. An over 
expression of MDR1 or P-gp in epileptogenic brain tissue of patients 
with different types of multidrug-resistant epilepsy, has been 
demonstrated leading to the multidrug-transporter hypothesis of 
medically intractable epilepsy. Consistent with its profile, BM had a 
beneficial effect on oxidative stress parameters (MDA and GSH) in 
our study. Specifically the potential to prevent the development of 
tolerance to antiepileptic effects of PHB by co-administration of BM 
observed in our study is fascinating from multiple viewpoints. 
Firstly such approaches can be valuable in preventing an incidence 
of pharmacoresistance. Secondly co-administration strategies can 
lead to a reduction in the dose of the primary epileptic drug (in this 
case PHB) leading to reduce side effects associated with AED. Thirdly 
co-administration strategies can significantly improve therapeutics 
outcomes due to collateral benefits in improving cognitive functions 
on top of effectively achieving antiepileptic effects.  
Effect of BM on tolerance  
The mechanism by which BM prevented the development of 
tolerance to antiepileptic effects of PHB is although not clear. It 
could be speculated that the effects of BM on P-gp or antioxidant 
activity directly or indirectly via P-gp or its effects on ion channels, 
GABA channels and acetylcholinestrase inhibition may be involved. 
Nevertheless this warrants further investigation. Additionally 
cognitive and behavioral problems are of major concern in patients 
with intractable epilepsy; hence we analyzed the cognitive impact of 
BM using a battery of behavioral tests. Indeed impacting behavioral 
changes in rats were shown to be a predictor for pharmacoresistant 
epilepsy. We observed favorable effects of BM on behavioral 
parameters, which further supports, the co-administration of BM to 
achieve improved therapeutics effects of primary AED. 
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